Eagle Asset Management’s Viridian Therapeutics VRDN Stock Holding History

Eagle Asset Management’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$7.89M	Sell	313,130 -60,332	-16%	-$986K	0.04%	337
2024 Q2	$4.93M	Sell	373,462 -65,305	-15%	-$904K	0.03%	395
2024 Q1	$7.57M	Sell	438,767 -14,541	-3%	-$282K	0.04%	337
2023 Q4	$9.87M	Sell	453,308 -5,861	-1%	-$92.5K	0.05%	271
2023 Q3	$7.04M	Buy	459,169 +8,731	+2%	+$167K	0.04%	310
2023 Q2	$10.7M	Sell	450,438 -11,227	-2%	-$288K	0.06%	251
2023 Q1	$11.7M	Buy	+461,665	New	+$14.8M	0.07%	225

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Eagle Asset Management's VRDN Position: Q3 2024 in Review

Eagle Asset Management reduced its Viridian Therapeutics (VRDN) stake by 16% in Q3 2024, selling an estimated $986K and leaving 313,130 shares worth $7.89M. The position accounts for 0.04% of the portfolio, ranked #337.

Eagle Asset Management first reported a position in VRDN in Q1 2023 and has held it in 7 quarters since. The position peaked at $11.7M in Q1 2023. 165 funds tracked by Wall St. Rank hold VRDN as of Q3 2024.

Eagle Asset Management held 313,130 shares of Viridian Therapeutics worth $7.89M as of Q3 2024.
Eagle Asset Management sold 60,332 Viridian Therapeutics shares in Q3 2024, an estimated $986K.
Viridian Therapeutics made up 0.04% of Eagle Asset Management's portfolio in Q3 2024, its #337 holding.
Eagle Asset Management first reported a position in Viridian Therapeutics in Q1 2023 and has held it in 7 quarters since.
Eagle Asset Management's Viridian Therapeutics position peaked at $11.7M in Q1 2023.
165 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2024.

Based on Eagle Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.